The evaluation efficacy of Desmopressin (1-deamino-8-D arginine Vasopressin) in increasing coagulation factor V and VIII in patients with combined factor V and VIII deficiency.

Vice chancellor for research, Mashhad University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•Confirmed affection with combined factor V and VIII deficiency using an identification card of hemophilia center or coagulation laboratory sheet showing diagnosis of combined factor V and VIII deficiency;
•Having more than 18 years old officially;
•Agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume;
•Not infusion of factor VIII during last 48 hours;
•Not infusion of fresh frozen plasma or cryopercipitate during last 48 hours;
•6-Not having active bleeding in time of accompanying in research.
•Exclusion criteria:
•1-Affection to other similar coagulation disorders, inter alia, combined factor VIII & IX deficiency.
•2-Havingless than 18 years old officially.
•3-Not agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume.
•4-Infusion of factor VIII during last 48 hours.
•5-Infusion of fresh frozen plasma during last 48 hours.
•6-Having active bleeding in time of accompanying in research.

发起方

Vice chancellor for research, Mashhad University of Medical Sciences